This company is no longer active
Graphite Bio Future Growth
Future criteria checks 0/6
Graphite Bio is forecast to grow earnings at 36.4% per annum. EPS is expected to grow by 73.8% per annum.
Key information
36.4%
Earnings growth rate
73.8%
EPS growth rate
| Biotechs earnings growth | 26.9% |
| Revenue growth rate | n/a |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | 15 Nov 2023 |
Recent future growth updates
Recent updates
Here's Why We're Watching Graphite Bio's (NASDAQ:GRPH) Cash Burn Situation
Sep 20
We're Hopeful That Graphite Bio (NASDAQ:GRPH) Will Use Its Cash Wisely
Jun 02Will Graphite Bio (NASDAQ:GRPH) Spend Its Cash Wisely?
Feb 01Here's Why We're Watching Graphite Bio's (NASDAQ:GRPH) Cash Burn Situation
Oct 05Graphite Bio doses first patient with GPH101 for sickle cell disease
Aug 11Will Graphite Bio (NASDAQ:GRPH) Spend Its Cash Wisely?
Jun 22Graphite Bio: Selling For Much Less Than Net Cash
May 25Graphite Bio: An Important Stock To Track In The Gene Editing Space
Nov 18Graphite Bio (NASDAQ:GRPH) Is In A Good Position To Deliver On Growth Plans
Sep 25Graphite Bio: Assessing Prospects Amid Doubts Raised On Safety Of Crispr
Aug 30Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | N/A | -23 | N/A | N/A | 1 |
| 12/31/2025 | N/A | -23 | N/A | N/A | 1 |
| 12/31/2024 | N/A | -23 | N/A | N/A | 1 |
| 12/31/2023 | N/A | -125 | -101 | -90 | N/A |
| 9/30/2023 | N/A | -126 | -78 | -67 | N/A |
| 6/30/2023 | N/A | -129 | -87 | -79 | N/A |
| 3/31/2023 | N/A | -99 | -92 | -88 | N/A |
| 12/31/2022 | N/A | -101 | -95 | -88 | N/A |
| 9/30/2022 | N/A | -95 | -88 | -81 | N/A |
| 6/30/2022 | N/A | -85 | -84 | -74 | N/A |
| 3/31/2022 | N/A | -77 | -75 | -66 | N/A |
| 12/31/2021 | N/A | -71 | -59 | -53 | N/A |
| 9/30/2021 | N/A | -115 | -48 | -43 | N/A |
| 6/30/2021 | N/A | -104 | -32 | -30 | N/A |
| 3/31/2021 | N/A | -88 | -19 | -17 | N/A |
| 12/31/2020 | N/A | -68 | -10 | -9 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: GRPH is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: GRPH is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: GRPH is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: Insufficient data to determine if GRPH's revenue is forecast to grow faster than the US market.
High Growth Revenue: GRPH is forecast to have no revenue next year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if GRPH's Return on Equity is forecast to be high in 3 years time
Discover growth companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/03/21 11:43 |
| End of Day Share Price | 2024/03/21 00:00 |
| Earnings | 2023/12/31 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Graphite Bio, Inc. is covered by 8 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Konstantinos Biliouris | BMO Capital Markets Equity Research |
| Gregory Harrison | BofA Global Research |
| Yun Zhong | BTIG |